Acorda. Company Leadership. Management Team; Board of Directors; Partnering With Acorda; Grant Program; Scientific Award; Compliance. Acorda Compliance; Biotie EFPIA Discolsures; Message From BIO; Diversity and Inclusion; Contact Us; For Patients. Focus On Therapies; In the Community; Resources; Policy on Access to Unapproved Medicines; Products & Research. Pipeline; ARCUS® Technology
Acorda Therapeutics, Inc. (ACOR) Company Press Releases – Get the latest press release for Acorda Therapeutics, Inc. and all the companies you research at NASDAQ.com
Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.
Acorda Therapeutics (Nasdaq:ACOR) ... Forward-looking statements made in this press release are made only as of the date hereof, ...
Updated news for Acorda Therapeutics Inc. - including ACOR company news, press releases and other industry & stock market news.
Acorda will obtain worldwide rights to tozadenant, ... Investor News Acorda to Acquire Biotie Therapies. ... This press release is issued pursuant to Rule 135(c) ...
Acorda Therapeutics to Acquire Civitas Therapeutics. Company to host webcast at 8:30 a.m. ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that it entered into an agreement to acquire Civitas Therapeutics, a privately-held biopharmaceutical company, for $525 million in cash.
Acorda Provides Update on Tozadenant Development Program. ... About Acorda Therapeutics. ... This press release includes forward-looking statements.
Acorda is dedicated to the development and commercialization of novel therapies that restore function and improve the lives of people with a range of nervous system disorders.
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Andrew Hindman, Acorda’s Chief Business Development Officer, will present at the Oppenheimer ...